Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov:31 Suppl 26:14-16.
doi: 10.1111/pai.13374.

Anti-IL-5 in pediatric allergic diseases

Laura Tenero  1 , Elisa Arturi  1 , Michele Piazza  1 , Giorgio Piacentini  1
Affiliations

Anti-IL-5 in pediatric allergic diseases

Laura Tenero et al. Pediatr Allergy Immunol. 2020 Nov.

Abstract

Interleukin (IL)-5 is a potent mediator of the inflammatory cascade in the allergic response. Its predominant role in atopic reactions makes this cytokine an ideal target for blocking the eosinophilic inflammatory hyper-responsiveness to allergens. The management of allergic diseases in childhood-such as severe asthma, atopic dermatitis, and eosinophilic esophagitis-is a challenge. In particular, there are concerns regarding the use of high-dose corticosteroids. Over the last few years, biologics targeting IL-5 or IL-5 receptor-that are mepolizumab, reslizumab, and benralizumab-represent a new, promising, and more personalized therapeutic option.

Keywords: IL-5; asthma; benralizumab; biologics; children; mepolizumab; reslizumab.

PubMed Disclaimer

References

REFERENCES

    1. Tenero L, Rossignoli S, Piacentini G. Severe asthma: When to resort to biological agents. Pediatr Allergy Immunol. 2020;31(S24):37-39.
    1. Licari A, Castagnoli R, Brambilla I, et al. Asthma endotyping and biomarkers in childhood asthma. Pediatr Allergy Immunol Pulmonol. 2018;31:44-55.
    1. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database of Systematic Reviews. 2017;9. Art. No.: CD010834.
    1. Gupta A, Steinfeld J, Price R, Azmi J, Bradford E, Yancey S. Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults. Eur Respir J. 2018;52:PA5447.
    1. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A. Consensus based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32:850-878.